Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples